Auf keinen Fall langweilig - Ein Kapitalmarktausblick auf 2022 | Jetzt im Magazin lesen | Allvest powered by Allianz-w-
06.12.2021 11:57

The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron

Folgen
Werbung
For Immediate ReleaseChicago, IL – December 6, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Moderna, Inc. MRNA, Pfizer Inc. PFE, BioNTech SE BNTX, Johnson & Johnson JNJ and Regeneron Pharmaceuticals, Inc. REGN.Here are highlights from Friday’s Analyst Blog:Covid-19 Vaccine and Drug Makers Gear Up to Fight OmicronThe pharma, biotech and medical devices companies played a vital role in bringing the pandemic slightly under control by making vaccines, diagnostic tests and medicines/antibodies to treat COVID-19. The vaccines allowed global economies to recover, to some extent, after crashing in the first half of 2020 when the pandemic began.Just when countries like the United States and Europe were seeing signs of the disease slowing down after third/fourth waves, the Omicron variant (B.1.1.529) has spread a sense of dread across much of the world.The Omicron variant, which was first detected in South Africa and Botswana, has a large number of mutations. Some of these mutations are associated with a decrease in antibody protection and higher transmission, per the World Health Organization (WHO). The potential high risks of the Omicron variant led the WHO to add it to its “Variant of Concern” list on Nov 26. So far, around two dozen countries across the world have reported cases of the Omicron variant.The fear of the variant is high due to concerns that it is potentially more contagious than the highly transmissible Delta variant and also due to its ability to bypass the protections provided by the currently available vaccines. The Omicron variant has ignited fears that the currently available COVID-19 vaccines and treatments could be less effective against it.Per a Financial Times article published on Nov 30, Moderna’s chief executive officer (“CEO”) Stéphane Bancel warned that the heavily mutated Omicron variant may reduce the effectiveness of its authorized COVID-19 vaccine or booster dose. Moderna CEO stated that it will take several months before an Omicron-specific booster can be made available in large quantities to vaccinate a large number of citizens.On the other hand, rival Pfizer partner BioNTech believe their vaccine will likely offer strong protection against any severe disease from Omicron variant. Getting a third or “booster” shot of their vaccine should provide further protection against Omicron infection.Omicron has once again shifted the focus on pharma/biotech companies in the hope that they make redesigned vaccines or drugs to combat this new mutation of the virus. Some vaccine makers including Moderna and J&J have announced their strategies for developing updated vaccines and boosters in order to respond to this variant. Companies like Regeneron, making monoclonal antibody treatments for COVID-19, have also responded on how their medicines work against Omicron.Moderna has already tested a 100-microgram booster dose, compared to its authorized booster dose of 50-microgram of its COVID-19 vaccine, mRNA-1273. The higher dose of its booster dose has resulted in the highest neutralizing titers against prior SARS-CoV-2 strains. Moderna is now rapidly testing sera from participants of high-dose booster studies to see if the dose provides neutralizing protection against Omicron.Secondly, Moderna is also testing its two other existing multi-valent booster candidates against the Omicron variant. Thirdly, Moderna is also planning to develop an Omicron-specific booster candidate.J&J is testing the effectiveness of its single-dose COVID-19 vaccine against the Omicron variant. The company is testing the blood serum from participants of completed and ongoing booster studies for neutralizing activity against the Omicron variant.J&J is also pursuing a new vaccine against Omicron, which will be pushed to clinical development, rapidly, if needed.Pfizer and BioNTech’s COVID-19 vaccine, Comirnaty is reportedly being tested to see if antibodies found in the blood of people vaccinated with their shot works against Omicron. Pfizer and BioNTech expect to be able to ship redesigned Comirnaty, if needed, to provide protection against the Omicron variant in approximately 100 days per a Reuters article.Novavax, whose vaccine is not yet authorized in the United States, is also evaluating its vaccine against the Omicron variant. Novavax has also begun developing an Omicron-specific vaccine construct. With regard to companies making monoclonal antibodies to treat COVID-19, Regeneron said that its antibody cocktail, REGEN-COV could be less effective against Omicron. Further tests are being conducted to understand the impact using the actual Omicron variant sequence.Regeneron’s REGEN-COV comprises two monoclonal antibodies, casirivimab and imdevimab and has been effective against the Delta variant, which is the predominant strain in the United States at present.Reportedly, Lilly is working to understand how its COVID-19 antibody cocktail, bamlanivimab plus etesevimab, works against Omicron. Gilead, reportedly, believes its drug Veklury (remdesivir) may continue to be effective against Omicron. Glaxo and partner Vir Biotech said that the pre-clinical data showed that their monoclonal antibody candidate, sotrovimab, retains activity against key mutations of the Omicron variantMeanwhile, new oral antiviral pills, Paxlovid and molnupiravir, respectively from Pfizer and Merck, are expected to hold up well against the variant and help reduce the severity of infections, if authorized by the FDA. Both companies have filed applications with the FDA for emergency use approval for the pills.The monoclonal antibody makers may be required to update their medicines in case Omicron becomes widespread.Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.com                                      https://www.zacks.com                                           Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Investor Alert: Legal Marijuana Looking for big gains?Now is the time to get in on a young industry primed to skyrocket from $13.5 billion in 2021 to an expected $70.6 billion by 2028.After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could kick start an even greater bonanza for investors. Zacks Investment Research has recently closed pot stocks that have shot up as high as +147.0%.You’re invited to immediately check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report To read this article on Zacks.com click here.
Weiter zum vollständigen Artikel bei "Zacks"
Ausgewählte Hebelprodukte auf BioNTech (ADRs)
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Produkte auf BioNTech (ADRs)
Long
Short
Hebel wählen:
5x
10x
Hebel
KO
Emittent
Laufzeit
Quelle: Zacks

Nachrichten zu BioNTech (ADRs)

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu BioNTech (ADRs)

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
19.01.2022BioNTech (ADRs) NeutralGoldman Sachs Group Inc.
12.01.2022BioNTech (ADRs) NeutralGoldman Sachs Group Inc.
05.01.2022BioNTech (ADRs) BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
16.12.2021BioNTech (ADRs) Equal-weightMorgan Stanley
09.12.2021BioNTech (ADRs) HoldDeutsche Bank AG
05.01.2022BioNTech (ADRs) BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
08.12.2021BioNTech (ADRs) BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
29.11.2021BioNTech (ADRs) BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
05.10.2021BioNTech (ADRs) BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
10.08.2021BioNTech (ADRs) BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
19.01.2022BioNTech (ADRs) NeutralGoldman Sachs Group Inc.
12.01.2022BioNTech (ADRs) NeutralGoldman Sachs Group Inc.
16.12.2021BioNTech (ADRs) Equal-weightMorgan Stanley
09.12.2021BioNTech (ADRs) HoldDeutsche Bank AG
08.12.2021BioNTech (ADRs) HoldJefferies & Company Inc.

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für BioNTech (ADRs) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

Nach Fed-Entscheid: Dow Jones taucht letztlich ab -- DAX schließt mit kräftigem Sprung -- Tesla schlägt Erwartungen -- Deutsche Bank, Siltronic, RWE, WACKER CHEMIE, Microsoft, Boeing, TI im Fokus

BVB-Aktie: Haaland gibt nach Verletzung Entwarnung. MAN macht München zum Leitwerk für Elektromobilität. VERBIO schraubt Gewinnprognose erneut nach oben. BioNTech plant starken Stellenausbau am Standort Marburg. adidas will 2022 mehr als 2.800 Stellen schaffen. Hypoport stärkt Versicherungsplattform mit Übernahme. Marktforscher - Apples iPhone Nummer eins in China.

Umfrage

Halten Sie es für richtig, dass die EZB an ihrer lockeren Geldpolitik festhält?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln